Drug Trial Radar · NCT07695246
Efficacy of CBT-I With Adjuvant Melatonin in Older Adults Chronic Insomnia
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
183
Planned (sponsor's estimate)
Start
Aug 1, 2026
Primary completion
Aug 1, 2029
Study completion Aug 1, 2029
Sponsor
- Lead sponsor
- The University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chinese University of Hong Kong
- First posted
- Jul 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study tests the efficacy of cognitive behavioural therapy for insomnia (CBT-I) with or without adjunct melatonin in older adults with insomnia. Adults aged 60 or above with chronic insomnia will be randomly assigned to one of three groups: (1) CBT-I plus nightly melatonin, (2) CBT-I plus nightly placebo tablet, or (3) sleep health psychoeducation plus nightly placebo tablet. All group sessions occur weekly for four weeks.
Conditions
- Insomnia
- Aging
- Sleep Disorders
Interventions
Cognitive behavioural therapy for insomniaBehavioral
CBT-I is a multi-component, non-pharmacologic intervention that targets behavioural, cognitive, and physiological perpetuating factors of insomnia. Four group-based weekly sessions (120-min; 6-8 participants) will be delivered. Components: sleep psychoeducation, sleep hygiene, stimulus control, sleep restriction, relaxation training, cognitive restructuring (addressing dysfunctional beliefs about sleep), and relapse prevention. Delivered in-person by trained therapists supervised weekly by the PI.
Melatonin 3 mg immediate-releaseDietary supplement
Melatonin is a safe and accessible sleep-promoting supplement. The tablet will be taken once daily, 30 minutes before habitual bedtime for 4 weeks, concurrent with CBT-I.
PsychoeducationBehavioral
Four group-based weekly sessions covering sleep hygiene, healthy diet, and exercise habits for older adults. This arm will not include any active therapeutic CBT-I components. It serves as the active control, controlling for attention and non-specific expectancy effects.
Placebo Oral TabletDrug
Placebo capsule identical in appearance to the melatonin capsule, taken once daily, 30 minutes before habitual bedtime for 4 weeks. Used in CBT-I + Placebo and Psychoeducation + Placebo arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Insomnia Symptoms - Insomnia Severity IndexTime frame: Baseline, Mid-session (Week 2 of the intervention), Post-Treatment (one-week after treatment conclusion) for all participants, and at Post-Treatment 3-month and Post-Treatment 6-month for participants in the treatment groups.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sleep Research Clinic and Laboratory, Department of Psychology, The University of Hong Kong
Hong Kong, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.